All In MedTech

Company

Stereotaxis

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

Stereotaxis is on our public-company list (ticker STXS). Naming a company here is not a recommendation of it or of any security.

Financing

Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.

Public

Listed

STXS

NYSE · Stereotaxis, Inc.

Public float

$150M

Value of shares held by non-insiders on Jun 30, 2025

Revenue

$32.4M

Fiscal year ending Dec 31, 2025

Net income

-$21.6M

Fiscal year ending Dec 31, 2025

R&D spending

$9.4M

Fiscal year ending Dec 31, 2025

Cash

$4.0M

As of Sep 30, 2026

Long-term debt

$2.5M

As of Sep 30, 2026

Shares outstanding

100.9M

As of Oct 31, 2026

Capital raised as a public company

Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.

YearIPOStock soldLong-term debtConvertible debt
2025–$15.7M––
2024–$297K––
2023–$81K––
2022–$220K––
2021–$547K––

Private placements (Form D)

One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.

First saleTypeRaisedRound sizeInvestorsExemption and agentFiling
Jul 31, 2024Equity

Issued in a merger or acquisition; not counted as money raised

$3.0MOpen-ended1Rule 506(b)Form D ↗Aug 15, 2024
Aug 7, 2019Equity$25.0M$25.0M6Rule 506(b)Agent: Cowen and Company LLCForm D ↗Aug 21, 2019
Sep 29, 2016Equity$24.0M$24.0M12Rule 506(b)Form D ↗Oct 5, 2016

2 more funding rounds with a free account

Company details

From the company's latest Form D.

Legal name
Stereotaxis, Inc.
Headquarters
St.Louis, Missouri
Incorporated
Delaware over five years before filing
Entity type
Corporation
Revenue range
Decline to Disclose
Industry filed under
Other Technology

Executives, directors and promoters

As listed on the latest Form D.

    8 more people on the filing with a free account

    Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

    Investors

    5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

    The investor database is part of the paid tier

    For Stereotaxis we have 1 shareholder with 5% or more and 1 government grant totalling $50K.

    It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.

    Latest FDA decisions

    The 8 newest of 9 since 2015.

    Search the Clearance Tracker

    6 more FDA decisions with a free account

    Device trials

    Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

    Open in the Trial Radar
    • NCT06019845 · 150 participants (planned) · Start Jan 2, 2024 · Primary completion Dec 31, 2027

      Device: MAGiC™ · For: Arrhythmias, Cardiac

      Sites: Copenhagen, Denmark; Vilnius, Lithuania; Rotterdam, Netherlands · 4 sites in all

    • NCT07812818 · 40 participants (planned) · Start Oct 31, 2026 · Primary completion Jan 31, 2029

      Device: Cardiac ablation using the MAGiC Ablation Catheter · For: Supraventricular Tachycardia (SVT); Congenital Heart Disease (CHD)

    • NCT04171479 · 40 participants · Start Oct 2, 2020 · Primary completion Mar 30, 2023

      Device: Epicardial mapping and/or ablation · For: Ventricular Tachycardia; Premature Ventricular Contraction

      Sites: Prague, Czechia; Amsterdam, Netherlands; Rotterdam, Netherlands

    6 more trials with a free account

    Reports received

    1

    Received Nov 1, 2025 to Nov 20, 2026

    Malfunction reports

    1

    100% of reports

    Injury reports

    0

    0.0% of reports

    Death reports

    0

    0.0% of reports

    Adverse event reports received per month

    Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

    Search the MAUDE Monitor
    • Malfunction
    • Injury
    • Death
    • Other
    View as table
    MonthMalfunctionInjuryDeathOther
    Dec 230000
    Jan 240000
    Feb 240000
    Mar 240000
    Apr 240000
    May 240000
    Jun 240000
    Jul 240000
    Aug 240000
    Sep 240000
    Oct 240000
    Nov 240000
    Dec 240000
    Jan 250000
    Feb 250000
    Mar 250100
    Apr 250000
    May 250000
    Jun 250000
    Jul 250000
    Aug 250000
    Sep 250000
    Oct 250000
    Nov 251000
    Dec 250000
    Jan 260000
    Feb 260000
    Mar 260000
    Apr 260000
    May 260000
    Jun 260000
    Jul 260000
    Aug 260000
    Sep 260000
    Oct 260000
    Nov 260000

    Device types named most often

    Last 12 months, by FDA product code. A company that sells more gets more reports.

    Brand names named most often

    Last 12 months, as written on the reports. One product can appear under several spellings.

    Recent recalls

    From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

    4 more recall records with a free account

    Back to all tools

    For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.